Search results for "ovarian neoplasm"

showing 10 items of 153 documents

Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer

2007

Abstract Objective. Docetaxel and carboplatin are active in relapsed ovarian, peritoneal and tubal cancer. Recently, two prospective-randomized trials showed an advantage of carboplatin combination regimen with paclitaxel or gemcitabine over carboplatinum alone in platinum-sensitive cases. The question on the most effective combination with the best tolerable side effects still needs to be answered. Methods. Eligible patients had recurrent ovarian, peritoneal or tubal cancer (platinum-free interval >6 months), performance status 0–2 and normal bone marrow, renal and hepatic function. 25 patients (age 18–75 years) were enrolled into this phase II trial. Patients with debulking operation of r…

AdultOncologymedicine.medical_specialtyPopulationDocetaxelGastroenterologyDisease-Free SurvivalCarboplatinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFallopian Tube NeoplasmsHumanseducationPeritoneal NeoplasmsAgedOvarian Neoplasmseducation.field_of_studyPerformance statusbusiness.industryObstetrics and GynecologyCancerMiddle AgedDebulkingmedicine.diseaseGemcitabineCarboplatinRegimenOncologyDocetaxelchemistryDrug Resistance NeoplasmFemaleTaxoidsNeoplasm Recurrence Localbusinessmedicine.drugGynecologic Oncology
researchProduct

Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Coho…

2009

Abstract Background: Several reproductive and hormonal factors are known to be associated with ovarian cancer risk in the general population, including parity and oral contraceptive (OC) use. However, their effect on ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has only been investigated in a small number of studies. Methods: We used data on 2,281 BRCA1 carriers and 1,038 BRCA2 carriers from the International BRCA1/2 Carrier Cohort Study to evaluate the effect of reproductive and hormonal factors on ovarian cancer risk for mutation carriers. Data were analyzed within a weighted Cox proportional hazards framework. Results: There were no significant differences in the risk of ova…

AdultOncologymedicine.medical_specialtyendocrine system diseasesSterilization TubalEpidemiologyPopulationCohort StudiesPregnancyRisk FactorsInternal medicinemedicineHumanseducationProportional Hazards ModelsBRCA2 ProteinOvarian NeoplasmsGynecologyTubal ligationeducation.field_of_studyBRCA1 Proteinbusiness.industryProportional hazards modelHazard ratioCancerMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsParityOncologyMutationFemalebusinessRisk assessmentOvarian cancerContraceptives OralCohort studyCancer Epidemiology, Biomarkers & Prevention
researchProduct

A case of late diagnosis and management of 46 XY complete gonadal dysgenesis in adulthood

2021

AdultOvarian NeoplasmsPediatricsmedicine.medical_specialtyDelayed Diagnosisbusiness.industryObstetrics and GynecologyGonadal dysgenesisGonadal Dysgenesismedicine.diseaseLate diagnosismedicineHumans46 XY complete gonadal dysgenesis; prophylactic gonadectomy; germ cell tumor; difference of sex developmentbusinessGinekologia Polska
researchProduct

Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas

1991

The expression patterns of intermediate filament proteins of primary and metastatic endometrial (n = 18) and ovarian (n = 24) adenocarcinomas were analyzed by immunocytochemistry using a panel of specific antibodies and by gel electrophoresis of cytoskeletal preparations, followed by immunoblotting. All cells of all endometrial adenocarcinomas studied contained the "simple epithelial"-type cytokeratins (CKs) 8, 18, and (mostly) 19, with variable numbers of cells also positive for CK 7 and vimentin. In addition, most of these tumors contained individual cells or groups of cells that were positive for the stratification-related CKs 4, 5, 6, 13, 14, and 17. The latter CKs were often associated…

AdultPathologymedicine.medical_specialtyCellular differentiationImmunocytochemistryVimentinAdenocarcinomaPathology and Forensic MedicineImmunoenzyme TechniquesIntermediate Filament ProteinsOvarian carcinomaGlial Fibrillary Acidic ProteinmedicineHumansIntermediate filamentAgedOvarian NeoplasmsbiologyCarcinomaMiddle Agedmedicine.diseaseEndometrial NeoplasmsSerous fluidMicroscopy Fluorescencebiology.proteinAdenocarcinomaElectrophoresis Polyacrylamide GelFemaleClear cellHuman Pathology
researchProduct

Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

2013

Paraneoplastic myelitis is a rare inflammatory disorder most frequently associated with solid tumors or lymphoproliferative disorders. Patients often harbor onconeuronal antibodies and their prognosis is usually poor. Here we report a 42-year old woman with longitudinally extensive transverse myelitis and aquaporin-4 (AQP4) antibodies that led to the diagnosis of ovarian teratoma. After tumor removal and immune therapy (including corticosteroids, plasma exchange, intravenous immunoglobulins and rituximab) the patient progressively improved achieving complete recovery. Histological study of the teratoma demonstrated neural tissue containing AQP4 expressing cells and intense inflammatory infi…

AdultPathologymedicine.medical_specialtyImmunologyLymphoproliferative disordersMyelitis TransverseAutoimmune diseases Paraneoplastic syndrome Transverse myelitisTransverse myelitisDiagnosis DifferentialmedicineImmunology and AllergyHumansNeurociènciesOvarian TeratomaAutoantibodiesAquaporin 4Ovarian Neoplasmsbiologybusiness.industryParaneoplastic MyelitisTeratomamedicine.diseaseNeurologybiology.proteinRituximabFemaleSistema nerviós MalaltiesNeurology (clinical)TeratomaAntibodybusinessBiomarkersmedicine.drugInflammatory disorder
researchProduct

Ovarian Endometrioid-like Yolk Sac Tumor Treated by Surgery Alone, with Recurrence at 12 Years

1999

Abstract We describe the case of a stage Ia endometrioid-like yolk sac tumor (YST) of the ovary, which was originally misdiagnosed as a malignant struma ovarii and not treated with adjuvant chemotherapy. After 12 years, a contralateral dermoid cyst was excised along with a small omental nodule of partially necrotic and calcified endometrioid-like YST. No tumor was detected in several other biopsy specimens, and a peritoneal lavage was negative for tumor cells. Since there was no evidence of remaining tumor and the serum α-fetoprotein (AFP) level was normal after the second operation, the patient was followed. Serial serum AFP levels remained normal for 4 months. At a second-look laparotomy …

AdultReoperationPathologymedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOvaryLaparotomyBiopsyHumansMedicineYolk sacPeritoneal NeoplasmsOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryEndodermal Sinus TumorObstetrics and GynecologyMalignant Struma Ovariimedicine.diseaseSurgerymedicine.anatomical_structureOncologyDermoid cystFemaleHistopathologyNeoplasm Recurrence LocalPouchbusinessOmentumGynecologic Oncology
researchProduct

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct

Laparoscopic staging of apparent early stage ovarian cancer: Results of a large, retrospective, multi-institutional series

2014

Abstract Objective The aim of this study is to analyze the safety, adequacy, perioperative and survival figures in a large series of laparoscopic staging of patients with apparent early stage ovarian malignancies (ESOM). Patients and methods Retrospective data from seven gynecologic oncology service databases were searched for ESOM patients undergoing immediate laparoscopic staging or delayed laparoscopic staging after an incidental diagnosis of ESOM. Between May 2000 and February 2014, 300 patients were selected: 150 had been submitted to immediate laparoscopic staging (Group 1), while 150 had undergone delayed laparoscopic staging (Group 2) of ESOM. All surgical, pathologic, and oncologic…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatmentGynecologic oncologyYoung AdultEarly ovarian cancer; Laparoscopy; Ovarian cancer; Adolescent; Adult; Aged; Aged; 80 and over; Child; Female; Humans; Laparoscopy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retrospective Studies; Young AdultOvarian cancerLaparotomymedicine80 and overHumansEarly ovarian cancer; Laparoscopy; Ovarian cancer; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Humans; Laparoscopy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retrospective Studies; Young AdultStage (cooking)LaparoscopyChildAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryOvarian cancer Early ovarian cancer LaparoscopyMedicine (all)Obstetrics and GynecologyRetrospective cohort studyPerioperativeMiddle Agedmedicine.diseasePrognosisSurgerySerous fluidSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyEarly ovarian cancerFemaleLaparoscopybusinessOvarian cancer
researchProduct

(Partial) loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes

2015

study hypothesis: Loss of protein BAF250a (ARID1A) expression is present in women with rectovaginal deep-infiltrating endometriosis (DIE) and endometriosis affecting the pelvic sentinel lymph nodes (PSLN). study finding: Partial loss of protein BAF250a was found in some of our patient samples, comprising all endometriosis entities, including rectovaginal DIE and endometriosis affecting the PSLN. what is known already: Loss of BAF250a (BRG-associated factor 250a)/ARIDIA (AT-rich interactive domain 1A) protein expression was identified among endometriosis-associated ovarian carcinomas and ovarian endometriosis, and this phenomenonwas described as a possible early event in the transformation o…

Adultmedicine.medical_specialtyBAF250a human proteinEmbryologyARID1APelvic sentinel lymph nodePopulationEndometriosisEndometriosisDeep-infiltrating endometriosiEndometriumGastroenterologyMalignant transformation03 medical and health sciencesEndometriumYoung Adult0302 clinical medicineGeneticInternal medicineGeneticsmedicinePTENHumanseducationMolecular BiologyCancerOvarian Neoplasmseducation.field_of_study030219 obstetrics & reproductive medicinebiologyCancerNuclear ProteinsObstetrics and GynecologyCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryARID1ADNA-Binding Proteinsmedicine.anatomical_structureReproductive Medicine030220 oncology & carcinogenesisOvarian Endometriosisbiology.proteinFemaleSentinel Lymph NodeTranscription FactorsDevelopmental Biology
researchProduct

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovaria…

2013

Summary Background In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7. Methods ICON7 is a randomised, multicentre, open-label phase 3 trial. Between Dec 18, 2006, and Feb 16, 2009, after a surgical procedure aiming to debulk the disease, women with Inter…

Adultmedicine.medical_specialtyBevacizumabDrug-Related Side Effects and Adverse ReactionsAntibodies Monoclonal HumanizedDisease-Free Survivallaw.inventionchemistry.chemical_compoundRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedNeoplasm StagingOvarian NeoplasmsIntention-to-treat analysisbusiness.industryStandard treatmentArticlesMiddle Agedmedicine.diseaseCarboplatinSurgeryBevacizumabClinical trialTreatment OutcomeOncologychemistryQuality of LifeFemaleOvarian cancerbusinessmedicine.drugThe Lancet Oncology
researchProduct